Ionis to get up to $300 million from licensing deal with AstraZeneca

(Reuters) - Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.